Krystal Biotech Inc

KRYS remains in a Stage 2 advancing structure with clear higher highs and higher lows confirming medium-term bullishness, but recent weakness has led to a healthy pullback into the 9EMA, 20EMA, and 50SMA support zone. Short-term timing is neutral as the pullback lacks visible acceptance, so execution is deferred until absorption and a clean bounce off key EMAs before initiating exposure.

• ↑Q1 net revenue $116.4M (+32% YoY; +9% sequential growth).
• ↑Gross margin 95% reflects efficient manufacturing processes.
• ↓Negative earnings yield suggests potential overvaluation risk.